banner

News

Apr 20, 2020
Category: Pipac
Posted by: pipac

Due to COVID-19, we are canceling the workshop on 4-5 June 2020.

Mar 17, 2020
Category: Pipac
Posted by: pipac

Workshop, Odense University Hospital, June 4-5, 2020:

Due to the COVID-19 situation there is a significant risk of cancellation of the Workshop. Final decision will be made no later than April 15th, 2020.

We will keep you informed through our website www.PIPAC.dk and ISSPP.org

Mar 13, 2020
Category: Pipac
Posted by: pipac

Due to the Corona virus, we are aware that it may affect our ability to hold our PIPAC workshop on June 4-5, 2020. We are closely following developments and will update the website for any changes.

Dec 17, 2019
Category: Pipac
Posted by: pipac

Fourth Scandinavian PIPAC workshop - June 4-5, 2020

 


Home

 

PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy) treatment of peritoneal carcinomatosis

Peritoneal carcinomatosis (PC) represents end stage disease in many types of cancer, and the majority of patients with PC will die from their disease within six months. Platinum-based systemic chemotherapy may prolong survival in selected patients, but poor performance status, low response rates, and treatment toxicity have led to conservative (nihilistic) treatment strategies in these patients. However, patients with PC who are in good condition and with a remaining life expectancy of more than a few months, may still have an unmet need for additional treatment in order to be able to perform with a high quality of life for as long as possible. These patients have often tried several lines of systemic chemotherapy (SC) with disappointing results, and alternative and more effective treatment strategies are desperately needed.

PIPAC is a minimal invasive administration of aerosolized chemotherapy within the abdominal cavity, which allow a high tissue concentration of chemotherapy without the usual side effects and toxicity of systematic chemotherapy. Clinical data suggest significant efficacy of PIPAC in platinum-resistant peritoneal metastasis with a confirmed low adverse events profile, and with no occupational health safety problems.

Odense PIPAC Center (OPC) introduced PIPAC in Scandinavia on October 29th, 2015. Since then, OPC has performed more than 700 PIPAC procedures, and published prospective data from both palliative and adjuvant studies. Further, PIPAC has evolved from in hospital treatment to a lenient procedure in the outpatient clinic.

More information on PIPAC is available at this homepage. We encourage both patients and health care personnel to use these resources and to contact us if additional information is needed.

 

If you need to contact Odense PIPAC Center, please feel free to contact us at this email: ouh.ode.a.pipac@rsyd.dk  

 



OUH